Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 378 Next >>

Filter Applied: myasthenia gravis (Click to remove)

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016

Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005

Neuroendocrine Lung Tumors and Disorders of the Neuromuscular Junction
Neurol 52:1490-1491, Burns,T.M.,et al, 1999

Fluoroquinolone Antibiotics Block Neuromuscular Transmission
Neurol 50:804-807, Sieb,J.P., 1998

Binocular Vertical Diplopia
Mayo Clin Proc 73:55-66, Brazis,P.W.&Lee,A.G., 1998

Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997

Exacerbation of Myasthenia Gravis Associated with Cocaine Use
Neurol 46:271-272, Daras,M.,et al, 1996

Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340, LeForestier,N.,et al, 1995

Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994

Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993

Ocular Myasthenia Gravis
J Natl Med Assoc 85:681-684, March,G.A.&Johnson,J.N., 1993

Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991

Myasthenia Gravis Unmasked by Cocaine Abuse
NEJM 325:892, Berciano,J.,et al, 1991

Citrate-Induced Impairment of Neuromuscular Transmission in Human and Experimental Autoimmune Myasthenia Gravis
Ann Neurol 27:328-330, Wirguin,I.,et al, 1990

Neuromuscular Blockade
Lancet 335:382-384, , 1990

Aggravation of Myasthenia Gravis by Erythromycin
Ann Neurol 28:577-579, May,E.F.&Calvert,P.C., 1990

Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990

Parkinson's Disease & Myasthenia Gravis:Adverse Effect of Trihexyphenidyl on Neuromuscular Transmission
Neurol 37:832-833, Ueno,S.,et al, 1987

Worsening of Myasthenia Gravis with Timolol Maleate Eyedrops
Ann Neurol 17:211-212, Verkijk,A., 1985

Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984

Procainamide-Induced Myasthenia-like Weakness in a Patient with Peripheral Neuropathy
Arch Neurol 38:378-379, Niakan,E.,et al, 1981

Ultrastructural Localization of Ach Receptor at the Motor Endplate:MG & Other Neuromuscular Dis
Neurol 30:1203-1211, Tsujihata,M.,et al, 1980

Single-fiber Electromyography in Myasthenia Gravis
Neurol 29:68-76, Sanders,D.B.,et al, 1979

Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979

Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978

Content of Acetylch Receptor & Antib Bound to Receptor in Myasth Gravis, Experi Autoimm Myasth Gravis, & Syndrome
Neurol 28:130, Lindstrom,J.M., 1978

Myasthenia Gravis, Study of Humoral Immune Mechanisms by Passive Transfer to Mice
NEJM 296:125, Toyka,K.V.,et al, 1977

Cause of Weakness in Myasthenia Gravis
NEJM 294:722, Grob,D., 1976

Acetylcholine Receptor Antibodies in Myasthenia Gravis
NEJM 293:760, Appel,S.H.,et al, 1975

Neuromuscular Junction in Myasthenia Gravis:Decreased Acetylcholine Receptors
Science 182:293, Fambrough,D.M.,et al, 1973

Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972

Histometric Anal. of Ultra-structure of Neuromuscular Junct. in Myasthenia Gravis & in the Myasthenic Syndr
Ann N Y Acad Sci 186:46, Engel,A.,et al, 1971

Myasthenic Syndrome in Patients with ALS
et al Neurol 9:627, Mulder,D.W., 1959

Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025

Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025

A Woman with Subacute Progression of Distal Upper Extremity Weakness
Neurol 105:e214212, Zhao,A.J.,et al, 2025

Ocular Myasthenia Gravis, Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator
Neurol 102:e209260, Young,A. & Johnston,J.L., 2024

The "Chameleon Eyes Sign" in Myasthenia Gravis
Neurol 103:e209756, Zara,P.,et al, 2024

Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024

Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024

Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Neurologic Manifestations of Hyperthyroidism and Graves Disease
www.UptoDate.com, Oct 28, Rubin,D.I., 2024

Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022



Showing articles 0 to 50 of 378 Next >>